RFA-AI-24-076: Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on March 13, 2025.
From the official notice on Grants.gov, last changed November 22, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR61 / R33
- Clinical trialsNot allowed
- Funded byNIAID
- Median yearly award$927,172
- Typical project length2 years
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under RFA-AI-24-076 were run by National Institute of Allergy and Infectious Diseases (NIAID, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AI-24-076 in the NIH Guide.
Key dates
| Posted | November 22, 2024 |
|---|---|
| Deadline | March 13, 2025 |
| Archived by Grants.gov | April 18, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity (NOFO) is to support preclinical activities for the development of safe and effective long-acting/sustained release (LA/SR) technologies for prevention and treatment of HIV and HIV-associated tuberculosis (TB), hepatitis B (HBV) and hepatitis C (HCV), and to ultimately advance these products toward submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Solicited LA/SR products will have demonstrated strong rationale, competitive advantage, and effectiveness in appropriate non-clinical or animal models at intermittent dosing from either a single administration (injection, topical, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.).
Funded under RFA-AI-24-076 so far
NIH funded 4 projects under RFA-AI-24-076 in fiscal 2026, at 4 institutions. The median yearly award was $927,172.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Ultra-long-acting in-situ forming implant (ISFI) as a subcutaneous injection for prevention of HIV and unplanned pregnancy | Univ of North Carolina Chapel Hill | 2026 | $1.1 million |
| A Single Long-Acting Injection For HBV Treatment Using Novel Entecavir Prodrugs For PWLH | The Scripps Research Institute | 2026 | $899,741 |
| TB LATITUDE (Long-Acting Treatment Innovation for TUberculosis Drug Effectiveness) | Global Alliance for TB Drug Development | 2026 | $802,418 |
| Novel Long-Acting HBV Capsid Assembly Modulators | Emory University | 2026 | $954,603 |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AI-24-076 still open?
No. It closed on March 13, 2025.
Who can apply for Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed)?
Closed March 13, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-AI-24-076?
NIH RePORTER lists 4 projects funded under RFA-AI-24-076 in fiscal 2026, at 4 institutions. The most were at Univ of North Carolina Chapel Hill, The Scripps Research Institute, Global Alliance for TB Drug Development.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)